2020
SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
Saffo S, Garcia‐Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. Journal Of Diabetes 2020, 13: 265-269. PMID: 33210815, DOI: 10.1111/1753-0407.13136.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBenzhydryl CompoundsCohort StudiesDiabetes Mellitus, Type 2FemaleGlucosidesGlycated HemoglobinHumansHypertension, PortalLiver CirrhosisMaleMiddle AgedOutcome Assessment, Health CarePolyuriaSodium-Glucose Transporter 2 InhibitorsTertiary Care CentersUrinary Tract InfectionsYoung AdultConceptsSGLT2 inhibitorsPortal hypertensionDiabetes mellitusSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsCenter cohort studyCotransporter 2 inhibitorsCohort of patientsPotential therapeutic targetFavorable pleiotropic effectsCohort studyRenal diseaseClinical trialsClinical dataTherapeutic targetPatientsCirrhosisHypertensionMellitusOngoing evaluationInhibitorsPleiotropic effectsCohortDiseaseTrials
2012
The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume Paracentesis
Bari K, Miñano C, Shea M, Inayat IB, Hashem HJ, Gilles H, Heuman D, Garcia–Tsao G. The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume Paracentesis. Clinical Gastroenterology And Hepatology 2012, 10: 1169-1175. PMID: 22801062, PMCID: PMC3678262, DOI: 10.1016/j.cgh.2012.06.027.Peer-Reviewed Original ResearchConceptsPostparacentesis circulatory dysfunctionRecurrence of ascitesVasoconstrictor groupAlbumin groupRefractory ascitesAscites recurrenceCombination of midodrineCombination of octreotidePlacebo-controlled trialLarge-volume paracentesisEffective blood volumeTreatment of choiceSingle intravenous doseOral midodrinePreventing RecurrenceRenal failureCirculatory dysfunctionMedian timeSerum levelsIntravenous doseIntramuscular injectionIntravenous administrationAscitesMidodrineBlood volumePrognostic indicators of survival in patients with compensated and decompensated cirrhosis
Zipprich A, Garcia‐Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver International 2012, 32: 1407-1414. PMID: 22679906, PMCID: PMC3713489, DOI: 10.1111/j.1478-3231.2012.02830.x.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientPredictors of deathCompensated patientsPortal hypertensionPrognostic valueComplications of cirrhosisSignificant portal hypertensionStage 2 patientsVenous pressure gradientDecompensated patientsSystemic haemodynamicsVariceal hemorrhagePortal pressureIndependent predictorsMultivariable analysisClinical eventsDecompensated stagePrognostic indicatorStaging systemLonger survivalBACKGROUND/CirrhosisPatientsSurvival rateAnalyse survival
2009
Use of Over-the-Counter Analgesics Is Not Associated With Acute Decompensation in Patients With Cirrhosis
Khalid SK, Lane J, Navarro V, Garcia–Tsao G. Use of Over-the-Counter Analgesics Is Not Associated With Acute Decompensation in Patients With Cirrhosis. Clinical Gastroenterology And Hepatology 2009, 7: 994-999. PMID: 19394441, PMCID: PMC3777825, DOI: 10.1016/j.cgh.2009.04.015.Peer-Reviewed Original ResearchMeSH KeywordsAcetaminophenAdultAgedAged, 80 and overAlcohol DrinkingAnalgesics, Non-NarcoticAnti-Inflammatory Agents, Non-SteroidalCase-Control StudiesContraindicationsFemaleHospitalizationHumansLiverLiver CirrhosisMaleMiddle AgedNonprescription DrugsPainProspective StudiesSurveys and QuestionnairesYoung AdultConceptsNonsteroidal anti-inflammatory drugsAcute hepatic decompensationAnti-inflammatory drugsCirrhotic patientsAlcohol ingestionCounter analgesicsHepatic decompensationAlcoholic cirrhosisNonsteroidal anti-inflammatory drug useAnti-inflammatory drug useDecompensation of cirrhosisConsecutive cirrhotic patientsTertiary care hospitalEffect of analgesicsCase-control studyRecent alcohol ingestionRecent alcohol useAcetaminophen useLiver clinicNoncirrhotic controlsNoncirrhotic patientsAcute decompensationFurther decompensationCare hospitalConsecutive patientsIncidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis
Qamar AA, Grace ND, Groszmann RJ, Garcia–Tsao G, Bosch J, Burroughs AK, Ripoll C, Maurer R, Planas R, Escorsell A, Garcia–Pagan J, Patch D, Matloff DS, Makuch R, Rendon G, Group P. Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis. Clinical Gastroenterology And Hepatology 2009, 7: 689-695. PMID: 19281860, PMCID: PMC4545534, DOI: 10.1016/j.cgh.2009.02.021.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientHematologic indicesCompensated cirrhosisBaseline hepatic venous pressure gradientWhite blood cell countChild-Pugh scorePredictors of deathPrimary end pointVenous pressure gradientDevelopment of varicesKaplan-Meier analysisBlood cell countCombination of leukopeniaBaseline thrombocytopeniaVariceal bleedingClinical decompensationEsophageal varicesPrognostic significanceTransplant surgeryClinical significanceLeukopeniaThrombocytopeniaCirrhosisCell countVarices
1990
Selective portal-systemic shunts for bleeding portal hypertension.
Orozco H, Mercado M, Takahashi T, García-Tsao G, Guevara L, Hernandez-Ortiz J, Tielve M. Selective portal-systemic shunts for bleeding portal hypertension. Revista De Investigación Clínica 1990, 42 Suppl: 165-9. PMID: 19256158.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedChildEsophageal and Gastric VaricesFemaleGastrointestinal HemorrhageHumansHypersplenismHypertension, PortalKaplan-Meier EstimateLiver CirrhosisMaleMiddle AgedPatient SelectionPortal VeinPortasystemic Shunt, SurgicalPostoperative ComplicationsRecurrenceRetrospective StudiesSeverity of Illness IndexThrombosisYoung AdultConceptsSelective shuntPortal hypertensionOperative mortalityChild A groupChild A patientsGlobal operative mortalityPortal-systemic shuntsGood liver functionTreatment of choiceElective fashionSplenocaval shuntWarren shuntPostoperative periodA patientsShunt thrombosisLiver functionHypertensionShuntPatientsA groupThrombosisMortalityYear periodTreatmentYears